In September, as doctors prepared for a fall and winter COVID-19 surge across the U.S., they sounded alarms about inadequate supplies of the antiviral medication remdesivir to treat their patients. But that supply concern seems to have been addressed: Gilead, remdesivir’s U.S. manufacturer, confirmed that they are “meeting real-time, global demand” in an email to…
Colleen Stinchcombe
Colleen Stinchcombe writes about health, science, and the environment. Her work can be found at colleenstinchcombe.com.
